Camp4 Therapeutics reported a net margin of -706.75% for the quarter ended Jun 2026. These financial ratios cover 11 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2023 | Dec2023 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||
| EBT Margin | -3,341.71% | -2,036.66% | -1,458.28% | -840.01% | -1,663.90% | -3,467.24% | -939.80% | -706.75% | |||
| EBIT Margin | -3,525.14% | -2,152.45% | -1,526.81% | -870.27% | -1,717.11% | -3,671.26% | -1,010.12% | -752.11% | |||
| EBITDA Margin | -3,525.14% | -2,152.45% | -1,526.81% | -870.27% | -1,717.11% | -3,671.26% | -1,010.12% | -752.11% | |||
| Operating Margin | -3,525.14% | -2,152.45% | -1,526.81% | -870.27% | -1,717.11% | -3,671.26% | -1,010.12% | -752.11% | |||
| Net Margin | -3,341.71% | -2,036.66% | -1,458.28% | -840.01% | -1,663.90% | -3,467.24% | -939.80% | -706.75% | |||
| FCF Margin | -1,771.63% | -1,697.55% | -690.92% | -1,410.94% | 1,794.83% | -857.96% | -730.64% | ||||
| Efficiency | |||||||||||
| Assets AverageAssets Avg. | 49.84M | 70.54M | 57.02M | 68.83M | 102.10M | 111.63M | 99.44M | ||||
| Asset Utilization RatioAsset Util. | 0.01 | 0.02 | 0.05 | 0.06 | 0.03 | 0.04 | 0.04 | ||||
| Leverage & Solvency | |||||||||||
| Interest Coverage RatioInterest Cover | -262.51 | -162.36 | -218.00 | 96.79 | |||||||
| Times Interest Earned | -262.51 | -162.36 | -218.00 | 96.79 | |||||||
| Valuation | |||||||||||
| Price to EarningsP/E | -1.84 | -6.44 | -2.32 | -6.19 | -15.43 | -18.83 | -18.05 | ||||
| Price to SalesP/S | 37.55 | 93.97 | 19.53 | 102.92 | 535.15 | 176.97 | 127.56 | ||||
| Price to BookP/B | 0.39 | 1.56 | 0.73 | 1.39 | 3.90 | 7.41 | -327.45 | ||||
| Enterprise Value | -39.56M | 31.30M | -9.87M | 6.52M | 75.37M | 129.05M | 139.79M | ||||
| EV to EBIT | 2.82 | -2.39 | 0.76 | -0.48 | -5.90 | -9.87 | -10.45 | ||||
| EV to EBITDA | 2.82 | -2.39 | 0.76 | -0.48 | -5.90 | -9.87 | -10.45 | ||||
| Market Capitalization | 24.48M | 80.63M | 29.23M | 81.82M | 186.23M | 228.99M | 226.92M | ||||
| Price to FCFP/FCF | -2.12 | -5.54 | -2.83 | -7.29 | 29.82 | -20.63 | -17.46 | ||||
| EV to FCF | 3.42 | -2.15 | 0.95 | -0.58 | 12.07 | -11.62 | -10.75 | ||||
| EV to CFO | 3.50 | -2.19 | 0.95 | -0.58 | 12.07 | -11.73 | -11.01 | ||||
| Return Ratios | |||||||||||
| Return on Sales [ROS]ROS | -3,525.14% | -14,671.71% | -2,152.45% | -1,526.81% | -870.27% | -1,717.11% | -3,671.26% | -1,010.12% | -752.11% | ||
| Return on Capital Employed [ROCE]ROCE | -131.93% | -83.17% | -108.03% | -88.32% | -60.70% | -55.29% | -65.85% | ||||
| Return on Assets [ROA]ROA | -103.69% | -73.30% | -90.93% | -74.95% | -49.34% | -44.82% | -50.31% |